Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBIĀ®Ā (lecanemab)
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, āEisaiā) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Ma...
How does the approval and launch timeline of LEQEMBIĀ® compare to competitorsā pipeline candidates targeting early Alzheimerās disease?
What is the expected market uptake and reimbursement landscape for LEQEMBIĀ® in these EU markets compared to existing Alzheimerās therapies?
How will the launch of LEQEMBIĀ® in Austria and Germany affect Biogenās (BIIB) stock price and trading volume?
Symbol:
BIIB
13 days ago